Cellular macromolecules in tumor and tumor microenvironment

Cellular macromolecules in the tumor and tumor microenvironment (TME) encompass a broad spectrum of biological entities, including proteins, nucleic acids, lipids, and complex carbohydrates that drive oncogenesis and therapeutic resistance. These molecules are found both within the malignant cells themselves and in the surrounding stroma, which includes the extracellular matrix (ECM), immune cells, and vascular structures (Source: NIH National Cancer Institute). In the context of disease, these macromolecules facilitate essential processes such as sustained proliferative signaling, evasion of growth suppressors, and the induction of angiogenesis (Source: Hanahan and Weinberg, Cell). For instance, cell surface receptors like HER2 or PD-L1 are specific protein macromolecules that serve as critical focal points for targeted therapies and immunotherapies (Source: PubMed). While the term cellular macromolecules is too broad to represent a single therapeutic target, it defines the chemical landscape where drug interactions occur to disrupt tumor homeostasis. Therapeutic strategies often involve small molecules or monoclonal antibodies designed to bind these macromolecules to inhibit their functional activity or mark them for immune destruction (Source: Nature Reviews Drug Discovery). Consequently, characterizing these components is vital for identifying biomarkers and developing multi-targeted treatment regimens.

Other names

Tumor-associated macromoleculesTumor microenvironment componentsTME macromoleculesCancer-associated biological polymers

Drugs targeting these macromolecules act through various mechanisms including competitive inhibition of enzymes, blockade of ligand-receptor interactions, stabilization of microtubules, and induction of antibody-dependent cellular cytotoxicity (ADCC) (Source: PubMed).